

#### **ASX ANNOUNCEMENT**

# Lumos Diagnostics Enters Agreement with WellStreet Urgent Care to Advance FebriDx® Testing

### **Key Highlights**

- Agreement with WellStreet Urgent Care to advance FebriDx® testing through their joint venture with Piedmont Urgent Care in Atlanta, Georgia.
- WellStreet to procure and submit reimbursement claims for each FebriDx test.
- Program deployment to commence in October 2025.
- PHASE Scientific to lead distribution; Pro-spectus to manage billing data and claims analysis.
- Intention to progress into a national rollout across ~140 WellStreet locations in the US based on anticipated CLIA waiver grant.

**MELBOURNE, Australia (16 October 2025)** – Lumos Diagnostics Holdings Ltd (ASX: LDX, "Lumos" or the "Company"), a leader in rapid, point-of-care diagnostic technologies, is pleased to advise it has reached an agreement with WellStreet Urgent Care ("WellStreet") to advance testing and reimbursement for FebriDx® through WellStreet's joint venture with Piedmont Healthcare in Atlanta, Georgia. The program is expected to commence in October 2025.

The FebriDx testing will occur at a Piedmont Urgent Care location handling approximately 50 patients per day presenting with respiratory infections, providing volume and operational insight. WellStreet will procure the FebriDx® test through PHASE Scientific. Pro-spectus will oversee data management and reimbursement outcomes. The insights gained through this initiative will greatly assist in developing a robust process for establishing future coverage policies with national insurance organizations.

Should FebriDx® secure a CLIA waiver grant, the intention is to leverage this agreement as the foundation for a nationwide roll-out across WellStreet's approximately 140 urgent care locations in the US.

"This collaboration with Lumos to implement FebriDx® at one of our busiest urgent care centers reflects WellStreet's ongoing commitment to operational excellence and innovative patient care. The ability to embed a rapid respiratory test into our workflows aligns with our core mission to deliver high-quality health care across our network," said WellStreet Urgent Care Chief Operating Officer and Chief Medical Officer Dr. Michael Duchynski.

Commenting on the announcement, Doug Ward, CEO of Lumos Diagnostics said: "We are excited to partner with WellStreet to bring FebriDx® into a high-throughput, clinically integrated setting. This agreement will greatly assist in laying the groundwork for a scalable national roll-out, pending CLIA waiver. We also greatly value the role of PHASE Scientific and Pro-spectus in aiding in the rollout of this program."

-Ends-

This announcement has been approved by the Lumos Disclosure Committee.

#### **About WellStreet Urgent Care**

WellStreet Urgent Care brings clinical and operational expertise in developing and scaling urgent care networks with health system partners. It's more than 150 urgent care centers boast best-in-class patient experience scores and better than average wait times, making them a valuable community resource for convenient, high-quality care. WellStreet is part of the less than 10% of urgent care providers nationwide to receive accreditation from the Urgent Care Association and proactively pursues quality and compliance excellence, rising above the standard for the urgent care industry. With a focus on patient coordination, WellStreet is clinically integrated within health system partner electronic medical records, providing patients and their care teams with a full picture of care for continued support. For more information, visit www.wellstreet.com.

#### **About Lumos Diagnostics,**

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

## **Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

#### **Media Contacts:**

Haley Chartres – Australia H^CK Director haley@hck.digital +61 423 139 163

#### **Investor Contact:**

George Kopsiaftis
IR Specialist, IR Department
<u>ir@lumosdiagnostics.com</u>
+61 409 392 687

## **Company Registered Office:**

Lumos Diagnostics Holdings Ltd Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 info@lumosdiagnostics.com

+61 3 9087 1598